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Abstract
Purpose—Prognostic models have been proposed to predict survival for non-small-cell lung 
cancer (NSCLC). It is important to evaluate whether these models perform better than 
performance status (PS) alone in stage- and age-specific subgroups.
Patients and Methods—The validation cohort included 2060 stage I and 1611 stage IV 
NSCLC patients from 23 CALGB studies. For stage I, Blanchon (B), Chansky (C) and Gail (G) 
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models were evaluated along with the PS only model. For stage IV, Blanchon (B) and Mandrekar 
(M) models were compared with the PS only model. The c-index was used to assess the 
concordance between survival and risk scores. The c-index difference (c-difference) and the 
integrated discrimination improvement (IDI) were used to determine the improvement of these 
models over the PS only model.
Results—For stage I, B and PS have better survival separation. The c-index for B, PS, C and G 
are 0.61, 0.58, 0.57 and 0.52, respectively, and B performs significantly better than PS with c-
difference=0.034. For stage IV, B, M and PS have c-index 0.61, 0.64 and 0.60, respectively; B and 
M perform significantly better than PS with c-difference=0.015 and 0.033, respectively.
Conclusion—Although some prognostic models have better concordance with survival than the 
PS only model, the absolute improvement is small. More accurate prognostic models should be 
developed; the inclusion of tumor genetic variants may improve prognostic models.
Keywords
Independent validation; Non-small cell lung cancer (NSCLC); Performance status; Prognostic 
models
Introduction
Lung cancer is the leading cause of cancer death among both men and women in the United 
States [1]. Over 85% of lung cancer cases are non-small cell lung cancer (NSCLC) [2]. 
Performance status (PS) is a simple functional assessment based on daily physical activities. 
There are two mutually convertible scoring systems for PS: the Karnofsky score [3] and the 
ECOG score, also called Zubrod/WHO score [4]. While PS is criticized for its subjectivity 
[5] and lack of prediction for chemotherapy toxicity [6], PS has become a popular 
prognostic tool in practice [7] and is one of the most commonly used eligibility criteria and 
stratification factors in randomized trials [8].
Even with the success of PS, the lung cancer community has been keen on developing new, 
potentially more objective and accurate prognostic models. Four existing prognostic models 
for NSCLC patients are summarized in Table 1. It is not surprising that three of the four 
models include PS as one of the predictors. Blanchon et al. [9] developed a prognostic 
model (B model) using the data from 2979 NSCLC patients. The prognostic model was 
based on multivariate Cox regression modeling with baseline prognostic factors: age, 
histology, PS, sex and stage (I-IV). Chansky et al.[10] (C model) assembled data from 9137 
surgically resected NSCLC patients from North America, and used both Cox regression and 
recursive partitioning and amalgamation analyses to identify risk factors, including age, sex 
and stage (I-IIIA), and provide classification of risk groups. A prognostic model established 
by Gail et al. [11] (G model) using 392 early stage NSCLC patients. The prognostic model 
was based on a Weibull survival model with histology, PS, TNM staging and post-operative 
infections (empyema, pneumonia or wound infections) as risk predictors. Mandrekar et al. 
[12] developed a prognostic model (M model) using 782 advanced NSCLC patients. This 
model incorporated patient characteristics, such as age, PS, sex, stage and body mass index 
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(BMI), and pre-treatment laboratory values, such as hemoglobin (HGB) and white blood cell 
(WBC) count.
However, these models are not commonly used in clinical practice or clinical trial design. 
Compared to the PS only model, these models require additional prognostic factors and 
some factors (e.g. lab values) may not be readily available. Most of these models already 
include PS as a predictor in the statistical models, but the discriminative accuracies of these 
models relative to the PS only model have not yet been fully validated using data from 
independent studies.
Since 1988, the Cancer Leukemia Group B (CALGB) (now part of the Alliance for Clinical 
Trials in Oncology) has conducted phase II and III clinical trials with NSCLC patients. The 
goal of the present research was to evaluate the accuracy of the four externally developed 
prognostic models noted above, for predicting overall survival of stage I and stage IV 
NSCLC patients. The added value of these prognostic models in discriminating overall 
survival over the PS only model was a focus. Also, as these prognostic models were 
predominantly developed on young patients (defined as age <70 years), we were also 
interested in evaluating the performance of these prognostic models among elderly patients 
(defined as age ≥ 70 years).
Patients and Methods
Selection Criteria
This study utilized data from the CALGB clinical trials to validate four published prognostic 
models in stage I and stage IV NSCLC. We identified all NSCLC studies targeting either 
stage I or IV patients conducted between 1988 and 2009 by the CALGB. Stage II and III 
patients were excluded because of the limited number of patients. Ongoing trials and 
recently closed trials with pending publications, trials with missing staging, diagnosis and 
histology information were excluded. The 23 CALGB studies included in the validation 
analysis are listed in the supplementary material Table S1. Of note none of the trials 
included selected patients based on epidermal growth factor receptor (EGFR) mutation or 
anaplastic lymphoma kinase (ALK) rearrangement status. The validation cohort consists of 
2060 stage I (IA-IB) and 1611 stage IV NSCLC patients, among which 2453 patients were 
<70 years old and 1218 patients were ≥ 70 years old.
Prognostic Models
Calculations of the risk scores based on the four prognostic models are briefly summarized 
in Table 2. Details on variable definitions and risk score calculations can be found in the 
corresponding publications [9-12]. Risk groups generating potential separation of survival 
curves can be defined on mutually exclusive intervals of risk scores. Six risk groups for the 
B model are formed on the score ranges specified in Table 3 of Blanchon et al [9]. Five risk 
groups for the C model are formed based on the survival tree in Figure 2 of Chansky et al 
[10]. Three risk groups for the G model are formed based on the rule in Table 9 of Gail et al 
[11]. Risk group was not discussed in Mandrekar et al [12]. For illustration, we created five 
risk groups for the M model by grouping patients at the quintiles of the risk score.
Wang et al. Page 3













Statistical considerations for validation
TNM information captured at patient registration was used to determine staging according to 
AJCC version 6; Version 7 was not used because available information is not sufficient to 
convert all patients from version 6 stage to version 7 stage. If both pathological and clinical 
staging were available, pathological staging was used. Complete cases analysis was adopted 
as the primary method to handle missing variables; specifically patients with missing 
predictors were excluded from the validation cohort. Sensitivity analyses with multiple 
imputation (MI) to handle missing variables were also performed. The MI analysis was 
based on 5 imputed datasets and the estimates were combined using Rubin's method [36].
For stage I the B, C and G models were evaluated along with the PS only model. For stage 
IV, the PS, B and M models were evaluated. The assessments were conducted for young 
(defined as age < 70 years), elderly (defined as age ≥ 70 years), and all patients combined.
The outcome of interest was overall survival, defined as the time from registration to the 
time of death. Overall survival was censored at the date of last follow-up, when death was 
not observed. The survival curves between risk groups were compared using the Kaplan-
Meier method and the log-rank test. Hazard ratios for the different risk scores were 
calculated using a Cox proportional hazards model. Assuming 40% and 90% death rate for 
stage I and stage IV patients, respectively, in the validation cohort, we have at least 95% 
power to a hazard ratio 1.20 for a risk score with a standard deviation of 1.0 at a 2-sided 
significance level of 0.10 for both patient groups.
To ease comparison, all risk scores are standardized to scores between 0 and 10. We 
estimated c-index (c) for a global assessment of the concordance between risk score and 
survival [37]. The difference in c-index (c-difference) is a measure formed by subtracting 
the c-index of the PS model from the c-index of a risk score. The c-difference and its 
bootstrap confidence interval based on 1000 bootstrap samples were used to evaluate the 
improvement of concordance of a risk score over the PS only model. To facilitate the 
comparison of c-index estimates among different patient subgroups, a modified c-index, free 
of influence of censoring distribution was also estimated [38]. The c-difference is a rank 
based statistics and it has been show insensitive to detect small differences in the 
discrimination accuracy between predictive models. Integrated discrimination improvement 
(IDI) is a difference between improvement in average sensitivity and improvement in 
average (1-specificity) and has been proposed to address the insensitive issue c-index [39, 
40]. By presenting both statistics, we attempt to evaluate the added value of a risk score over 
the standard model. All statistical analyses were performed using SAS 9.3 (Cary, NC) and R 
3.0.1 (boot, rms, survC1 and survIDINRI packages).
Results
As seen in Table 3, for the 2060 stage I patients, the median age was 67.9 years (range 24 to 
95), 53.5% were male, 86.1% white, 64.7% PS=0, and 11.2% with weight loss ≥5% in the 
past 3 or 6 months prior to enrollment. The most common histology was adenocarcinoma 
(50.4%) followed by squamous histology (30%). A total 914 deaths were observed among 
the 2060 patients with a median follow-up time of 4.9 years.
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For the 1611 stage IV patients, the median age was 62.6 years (range 25 to 88), 63.4% were 
male, 83.1% white, 35.1% PS=0, and 34.2% had weight loss ≥5% in the past 3 or 6 months 
prior to enrollment. The most common histology was adenocarcinoma (55.8%) followed by 
squamous (18.5). Of these stage IV patients, a total of 1513 deaths in the 1611 patients were 
observed with a median follow-up time of 3.3 years.
Stage I Prognostic Models
For all stage I patients, the median survival was 6.55 years (95%CI: 6.09-6.95) and the 5-
year OS rate was 0.58 (95%CI: 0.56-0.61).The risk groups derived from the four prognostic 
models all yield statistically significant separation among the risk groups (log rank p-value 
<0.001). The risk groups of B, C and PS models correctly ordered the survival functions, in 
which higher risk groups yield worse survival (Figure 1), but the G model did not (Table 4). 
The risk score of the B model performed the best among all models in predicting survival of 
stage I patients. The hazard ratios for the B, C, G and PS models were 1.441, 1.126, 1.003 
and 1.238, respectively (Table 4). The c-indices for the B, C, G and PS models were 0.611, 
0.573, 0.519, and 0.580, respectively (Table 5). When the models were compared to the PS 
only model, the B model had a significant improvement in discriminating survival, as 
indicated by c-difference of 0.034 with a 95%CI (0.023-0.045) excluding zero, but not the 
integrated discrimination index (IDI) 0.029 (95%CI: −0.044-0.061) where the confidence 
interval included zero. Because 19% stage I patients in the validation cohort had missing 
risk scores for the C model, the multiple imputation (MI) analysis was used to evaluate the 
impact of the missing data on model evaluation. All performance measures from the MI 
analysis for the C model are very smiliar to those from the complete case analysis, for 
example, the hazard ratio and c-index are 1.13 and 0.58 for the MI analysis.
There is a statistically significant difference in survival between stage I young and old 
patients (log rank p-value< 0.0001) with median OS of 7.88 years (95%CI: 7.28-8.94) for 
young and 4.92 years (95%CI: 4.49-5.63) for old patients. The results of age group-specific 
validation are provided in the supplementary figures and tables (Figures S1-S2, Tables S2-
S4). The performances of the four prognostic models in young stage I patients, with c-
indices for B, C, G and the PS models of 0.587, 0.548, 0.536 and 0.564, respectively, 
resemble closely those seen in the entire cohort. Similar findings hold true for older stage I 
patients in that the B model was still the best model and significantly better than the PS 
model. As indicated clearly by c-difference and IDI, C and G models were significantly 
worse than the PS only model. The incorrect survival ordering of the risk groups of C and G 
models suggests they are inappropriate to use in patient prognostication and stratification for 
stage I NSCLC. Overall, the B model has the best performance in all stage I patients, in 
young stage I patients, as well as in old stage I patients, but compared to the PS only model, 
the absolute improvement in concordance between the B model risk score and survival was 
limited, ranging from 2.44%-3.48%.
Stage IV Prognostic Models
For all stage IV patients, the median survival was 8.25 months (95%CI: 7.79-8.87) and the 
6-month OS rate was 0.62 (95%CI: 0.60-0.65). The B, M and the PS models are applicable 
to stage IV patients. Because the predictors such as weight loss, WBC and HGB were 
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missing in approximately 30% of stage IV patients, the actual number of patients used in 
validating the M model was about 67% of the B model and the PS only model. Additional 
analysis was conducted using the subset of 1081 patients who have risk scores for both the B 
model and the M model. Because the findings are very similar, the results for patients with 
at least one risk score are reported here. The risk groups derived from the prognostic models 
yield statistically significant separation in survival (log rank p-value <0.001). The risk 
groups of all models produce a correct ordering of survival functions (Figure 1, Table 4). 
The c-indices for B, M and PS models were 0.611, 0.641 and 0.596, respectively (Table 5). 
Because 33% stage IV patients in the validation cohort had missing variables for the M 
model, the multiple imputations (MI) analysis was used to evaluate the impact of the 
missing data on model evaluation. All performance measures from the MI analysis are very 
similar to those from the complete case analysis, for example, the c-index from the MI 
analysis is 0.62 versus 0.61 from the complete case analysis. Both the B and M models 
performed better than the PS only model with c-difference=0.015 (95%CI: 0.008-0.023) and 
0.033 (95%CI: 0.020-0.046), respectively, with similar improvement in IDI indices. There 
were no significant differences in OS between stage IV young and old patients (log rank p-
value=0.347) with median OS 8.34 months (95%CI: 7.82-9.10) for young and 7.85 months 
(95%CI: 6.67-9.10) for older patients. As seen in the supplementary Figures S1-S2 and 
Tables S2-S4, similar performance patterns of these prognostic models hold in younger and 
older stage IV patients. Overall, the B and M models have significantly better discrimination 
than the PS only model in all stage IV patients, and in the younger and older subsets, but the 
absolute improvement in concordance between risks scores and survival is limited with a 
range of 2-5%.
Discussion
The objective of this analysis was to evaluate the accuracy of four externally developed 
prognostic models for predicting overall survival of stage I and stage IV NSCLC patients. 
We were particularly interested in the performance of these prognostic models in elderly 
lung cancer patients relative to younger patients, as elderly patients have been less 
investigated in clinical trials. Overall, the B model has the best prognostic capability for 
stage I and IV as well as younger and older patients. It uses easily measured covariates for 
computing risk scores and divides patients into 6 risk groups based on risk scores. For stage 
IV patients, the M model is particularly strong with the incorporation of additional variables, 
such as weight loss, WBC and HGB. One of the reasons why the C model may have 
performed poorly in stage I patients is that PS is not included in the model's definition of 
risk groups. The C model performs significantly worse than the PS only model in the elderly 
patients, and classifies the entire set of elderly patients as one risk group. The G model 
included similar predictors to the B model, including histology, stage and PS, with wound 
infection as a unique predictor. Unfortunately, in our validation cohort, infection data was 
not collected in about 80% patients of the stage I NSCLC trials; of 421 patients who had 
infection data recorded, there was only one patient reporting infection. For this reason, we 
assumed all stage I patients had no infection, or equivalently the regression coefficient of 
infection is zero, in the analysis. The relatively poor performance of the G model could be 
attributed to this and a few other reasons. For example, this model was developed on a 
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relatively small cohort (392 patients); it was not validated with internal or external datasets; 
and a parametric regression model was used to estimate risk score. It is interesting to note 
that most prognostic models using additional covariates fail to perform better for the PS only 
model for stage I, stage IV, old and young patients. The only exceptions are the B model in 
stage I and IV and the M model for stage IV, but the absolute improvement in concordance 
of B and M models over the PS model was still small, ranging from 2-5%, and IDI ranging 
from 0.001-0.029. Because of its simplicity and the small added value for the more 
complicated models for patients with stage I and stage IV disease, the PS only model may 
continue to be the most popular score for stratification in clinical trials. However, with the 
concordance of the PS model with survival being 0.58 for stage I and 0.60 for stage IV 
patients, PS alone remains a suboptimal prognostic model.
Prognostication of survival and adverse events is particularly important in elderly lung 
cancer patients, as these patients may be particularly vulnerable and have been less well 
studied than their younger counterparts. To date, prognostic models have been primarily 
developed using a younger patient population. As the results show, some of the existing 
models (e.g. B and G) are worse than the PS only model when used to predict survival in 
elderly patients. Comorbidity and other geriatric risk factors have previously shown a strong 
association with survival and chemotherapy-related toxicity in elderly lung cancer patients 
[6, 41]. None of these prognostic factors were used in the existing models, likely because 
these prognostic factors were not captured in the database used to develop these models. 
This may be why these models failed to provide a significant discriminative advantage over 
PS alone in elderly patients.
This study has limitations. Not every published prognostic model for NSCLC was 
compared. To avoid the issue of incomparability, prognostic model developed based on 
patients exclusively treated by one drug such as bevacizumab [42] was not chosen for 
comparison. While all relevant CALGB trials from 1988-2009 have been identified and 
included, the cohort of patients available for studying the elderly is still small. Most patients 
had good PS as required for trial eligibility which led to a small validation cohort for 
patients with poor PS. In the validation, like most of the prognostic models, we included 
patients who were treated by different surgical procedures, chemotherapy and radiation. 
Although it is important for prognostic models to predict outcome independent of the exact 
nature of the treatment paradigm, the heterogeneity introduced by treatment variation may 
have underestimated the absolute prediction accuracy of these models.
Given the limited success of the existing prognostic models, including PS alone model, there 
is a clear need for developing prognostic models that improve considerably upon PS alone, 
for patient stratification in stage- and age-specific clinical trials. Further research, including 
the application of geriatric assessment and frailty indicators, is needed to address these 
limitations, especially for the older and more vulnerable patients. Regardless, our study 
suggests that the predictive ability of existing more complex models is not meaningfully 
better than that of PS alone, particularly for older patients.
Lung cancer patients are at considerable risk for other causes of deaths due to their advanced 
age at diagnosis and smoking-related chronic diseases. The discriminative accuracy of a 
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prognostic model can be improved by taking the issue of competing risk into account. With 
the success of the identification of genetic alterations, such as EGFR mutations and ALK 
rearrangements, and development of targeted therapies for NSCLC, it has become clear that 
lung cancer is a heterogeneous disease. The prognostication and its treatment should 
incorporate the genetic profile of patients as well [43].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Prognostic models for stage I and stage IV NSCLC were validated using data 
from 23 CALGB trials
• For stage I, Blanchon (B), Chansky (C) and Gail (G) models were evaluated
• For stage IV, Blanchon (B) and Mandrekar (M) models were evaluated
• Some models have better concordance with survival than the PS only model, but 
the absolute improvement is small
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Survival Curves of Risk Groups in All Patients
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Table 1
Prognostic Models Investigated
B model C model G model M model
Citation Blanchon et al (2006) Chansky et al (2009) Gail et al (1984) Mandrekar et al (2006)
Geography Area France IASLC LCSG North America
Stage stage I-IV stage I-IIIa resected resected stage I advanced stage
Training n 2929 9137 392 782 from NCCTG
Validation n 1500 SEER 9221 na 433 from SWOG
Endpoint OS OS Recurrence, OS OS, TTP
OS: overall survival; TTP: time to progression; LCSG: Lung Cancer Study Group (LCSG); NCCTG: North Central Cancer Treatment Group; 
SWOG: Southwest Oncology Group
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Table 2
Prognostic model risk score
Prognostic Model Risk Score
B model 1×(if age>70) + 1×(if gender=Male) + 3×(if PS=1) + 5×(if PS=2) + 8×(if PS=3) + 10×(if PS=4) + 2×(if histology=Large-
cell) + 3×(if stage=IIA-IIB) + 6×(if stage=IIIA-IIIB) + 8×(if stage=IV)
C model log(1.35) ×(if Adenocarcinoma) + log(1.161) ×(if Squamous) + log(1.38159) ×(if Large cell) + log(1.353958) ×(if 
Adenosquamous) + log(1.21) ×(if gender=Male) + log(1.51) ×(if age≥70) + log(1.30) ×(if stage=IB) + log(1.872) ×(if 
stage=IIA) + log(2.4336) ×(if stage=IIB) + log(3.553056) ×(if stage=IIIA)
G model
1 −8.971 + 0.679× (if T1N0 Nonsquamous) + 0.103 × (if T1N1 Squamous) + 1.600 × (if T1N1 Nonsquamous) + 0.981 × 
(if T2N0 Squamous) + 1.282 × (if T2N0 Nonsquamous) + 0.450 × (if PS≥2)
M model 0.26 + 0×(if PS=0) + 0.48×(if PS=1) + 0.96×(if PS=2 or 3) + 0.60×(if underweight) + 0×(if normal weight) + 0.11×(if 
overweight) - 0.11 ×(if obese) + 0×(if normal HGB) + 0.41×(if abnormal HGB) + 0×(if normal WBC) + 0.35×(if high 
WBC)
(if x) is an indicator function which equals 1 if the statement ‘x’ is true and 0 otherwise.
1
Data on wound infection was not collected on 80% stage I NSCLC patients in the validation cohort. To evaluate the G model, we assumed all 
patients had no wound infection or equivalently the regression coefficient of infection is zero.
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Table 3
Patient Characteristics for Model Validation
Stage I (N=2060) Stage IV (N=1611)
Age (yrs)
    n 2060 1611
    Median 67.9 62.6
Age Group
    < 70 1194 (58.0%) 1259 (78.2%)
    ≥ 70 866 (42.0%) 352 (21.9%)
Sex
    Male 1102 (53.5%) 1022 (63.4%)
    Female 958 (46.5%) 589 (36.6%)
Race
    White 1773 (86.1%) 1338 (83.1%)
    Black 130 (6.3%) 191 (11.9%)
    Other 156 (7.6%) 81 (5.0%)
Histology
    Adenocarcinoma 1001 (50.4%) 894 (55.8%)
    Squamous 595 (30.0%) 297 (18.5%)
    Large Cell 82(4.1%) 143 (8.9%)
    Other 308 (15.5%) 268 (16.7%)
Performance Status
    0 1326 (64.7%) 565 (35.1%)
    1 648 (31.6%) 867 (53.8%)
    2 66 (3.2%) 177 (11.0%)
    3/4 9 (0.4%) 2 (0.2%)
Weight Loss
    < 5% 1497 (88.8%) 650 (65.8%)
    ≥ 5% 189 (11.2%) 338 (34.2%)
WBC ×109/L
    n 403 1238
    Median 7.8 8.7
HGB g/dL
    n 557 1110
    Median 13.4 13.0
BMI kg/m2
    n 1020 1519
    Median 26.4 25.0
Deaths 914 (44.4%) 1513 (93.9%)
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Table 4
Survival Analysis Results for All Age Groups
Stage Prognostic Model n (Events) Log Rank (p-value) Correct Order? HR (95%CI)
Stage 1 Blanchon 1977 (860) 128.90 (<.0001) yes (4,3,2,1) 1.44 (1.35, 1.54)
Chansky 1662 (755) 67.76 (<.0001) yes (3,2,1) 1.13 (1.09, 1.16)
Gail 1973 (856) 13.56 (0.0011) no (3,1,2) 1.00 (0.97, 1.04)
PS only 2049 (907) 107.30 (<.0001) yes (2,1,0) 1.24 (1.19, 1.29)
Stage 4 Blanchon 1602 (1506) 105.47 (<.0001) yes (6,5,4) 1.36 (1.30, 1.43)
Mandrekar 1084 (1043) 159.86 (<.0001) yes (5,4,3,2) 1.24 (1.20, 1.28)
PS only 1611 (1513) 128.29 (<.0001) yes (2,1,0) 1.20 (1.16, 1.24)
All risk scores standardized to the range [0, 10] for HR comparison.
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Table 5
c-index and its Difference Relative to PS only Model for All Age Groups
Stage Prognostic Model c (95% CI) c-difference (95% CI) IDI (95% CI)
All Patients
Stage 1 Blanchon 0.61 (0.59, 0.63) 0.034 (0.023, 0.045) 0.029 (−0.044, 0.061)
Chansky 0.57 (0.55, 0.60) −0.002 (−0.034, 0.026) −0.027 (−0.080, 0.059)
Gail 0.52 (0.50, 0.54) −0.057 (−0.085, −0.029) −0.053 (−0.561, 0.028)
PS only 0.58 (0.56, 0.60)
Stage 4 Blanchon 0.61 (0.60, 0.63) 0.015 (0.008, 0.023) 0.013 (0.007, 0.021)
Mandrekar 0.64 (0.62, 0.66) 0.033 (0.020, 0.046) 0.012 (0.001, 0.020)
M-B
1 0.018 (0.003, 0.033) −0.004 (−0.019, 0.008)
PS only 0.60 (0.58, 0.61)
1
Comparison between Mandrekar and Blanchon models.
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